C. R. Bard, Inc. (NYSE:BCR) has analysts on the Bullish side this week.

December 7, 2017 - By Linda Rogers

 C. R. Bard, Inc. (NYSE:BCR) has analysts on the Bullish side this week.
Investors sentiment decreased to 0.58 in Q2 2017. Its down 0.30, from 0.88 in 2017Q1. It fall, as 99 investors sold C. R. Bard, Inc. shares while 273 reduced holdings. 103 funds opened positions while 111 raised stakes. 55.14 million shares or 10.97% less from 61.93 million shares in 2017Q1 were reported.
Carlson Capital Limited Partnership reported 686,000 shares or 3.1% of all its holdings. Guyasuta Invest Advsrs Inc holds 0.15% or 3,832 shares in its portfolio. Rothschild Asset invested 0% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). Panagora Asset Inc reported 0.02% stake. Cambridge Invest Advsr Incorporated stated it has 0.01% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). Winslow Evans & Crocker reported 9,100 shares stake. Endurant Cap Ltd Partnership holds 3.29% or 36,761 shares. Nomura Asset Mngmt Limited has invested 0.04% in C. R. Bard, Inc. (NYSE:BCR). Lombard Odier Asset Mgmt (Europe) Ltd holds 988 shares. Thompson Davis Inc has invested 0.04% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Corp has invested 0.26% in C. R. Bard, Inc. (NYSE:BCR). Paloma Partners Mngmt owns 6,570 shares. Colonial Advsrs holds 0.79% of its portfolio in C. R. Bard, Inc. (NYSE:BCR) for 11,050 shares. Vanguard Group Inc Inc has 0.12% invested in C. R. Bard, Inc. (NYSE:BCR). Charter Trust Com owns 1,122 shares.

C. R. Bard, Inc. (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard had 32 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, September 22 by Needham. Wells Fargo upgraded the shares of BCR in report on Friday, September 16 to “Outperform” rating. On Monday, December 12 the stock rating was upgraded by BMO Capital Markets to “Outperform”. BMO Capital Markets downgraded C. R. Bard, Inc. (NYSE:BCR) rating on Wednesday, April 26. BMO Capital Markets has “Market Perform” rating and $245 target. The rating was maintained by Raymond James with “” on Wednesday, April 26. Raymond James upgraded the stock to “Strong Buy” rating in Thursday, January 5 report. The rating was maintained by BMO Capital Markets on Wednesday, October 11 with “Hold”. The rating was upgraded by Morgan Stanley to “Overweight” on Tuesday, January 3. Wells Fargo downgraded the shares of BCR in report on Wednesday, April 26 to “Market Perform” rating. BMO Capital Markets maintained the stock with “Buy” rating in Wednesday, April 12 report. Below is a list of C. R. Bard, Inc. (NYSE:BCR) latest ratings and price target changes.

06/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $245 New Target: $337 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
22/09/2017 Broker: Needham Rating: Hold Maintain
12/09/2017 Broker: Jefferies Rating: Hold New Target: $317.0 Maintain
31/08/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
28/07/2017 Broker: Cowen & Co Rating: Hold New Target: $317.0000 Maintain
28/07/2017 Broker: Needham Rating: Hold
10/07/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0000 Maintain
29/06/2017 Broker: Jefferies Rating: Hold New Target: $317.0000 Maintain

The stock increased 0.06% or $0.19 during the last trading session, reaching $332.07. About 569,167 shares traded or 16.85% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 7, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.21 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.8 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

More news for C. R. Bard, Inc. (NYSE:BCR) were recently published by: Investorplace.com, which released: “CR Bard (BCR) a Strong Buy on Exceptional Quant Score” on November 28, 2017. Bizjournals.com‘s article titled: “What Jabil’s new director signals about the company’s future” and published on November 30, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.